Lyell Immunopharma(LYEL)
$13.89+0.22 (+1.61%)
LYEL
Lyell Immunopharma financials statements
$13.89
At close:+0.22 (+1.61%)
Want to see LYEL full AI Analyst Report?
Lyell Immunopharma (LYEL) Ratios
163 Followers
Lyell Immunopharma Ratios
LYEL's free cash flow for Q3 2026 was $-34.63M. For the 2026 fiscal year, LYEL's free cash flow was decreased by $-66.00K and operating cash flow was $-34.57M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 |
| Quick Ratio | 5.28 | 7.06 | 16.07 | 17.59 | 13.40 |
| Cash Ratio | 1.22 | 1.96 | 4.22 | 3.34 | 6.29 |
| Solvency Ratio | -2.86 | -2.99 | -2.25 | -1.58 | -1.20 |
| Operating Cash Flow Ratio | -3.04 | -3.02 | -4.74 | -4.58 | -2.70 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 169.09M | $ 271.56M | $ 459.61M | $ 546.99M | $ 428.67M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.15 | 0.12 | 0.08 | 0.07 | 0.06 |
| Debt-to-Equity Ratio | 0.21 | 0.15 | 0.10 | 0.08 | 0.07 |
| Debt-to-Capital Ratio | 0.17 | 0.13 | 0.09 | 0.08 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.37 | 1.28 | 1.15 | 1.13 | 1.21 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.98 | 4.51 | 5.03 | 5.48 | 5.59 |
| Net Debt to EBITDA | 0.03 | 0.23 | 0.36 | 0.33 | 1.12 |
| Profitability Margins | |||||
| Gross Profit Margin | -31952.78% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -762355.56% | -361104.92% | -190006.15% | -220.89% | -2016.68% |
| EBITDA Margin | -730302.78% | -328922.95% | -174429.23% | -199.61% | -1888.75% |
| Operating Profit Margin | -566038.89% | -588122.95% | -190006.15% | -220.89% | -2016.68% |
| Pretax Profit Margin | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% |
| Net Profit Margin | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% |
| Continuous Operations Profit Margin | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 134.68% | 95.61% | 94.99% | 97.89% | 116.50% |
| Return on Assets (ROA) | -80.71% | -69.88% | -31.28% | -19.53% | -22.19% |
| Return on Equity (ROE) | -110.57% | -89.60% | -35.82% | -21.98% | -26.91% |
| Return on Capital Employed (ROCE) | -70.11% | -82.08% | -34.52% | -20.77% | -19.87% |
| Return on Invested Capital (ROIC) | -67.99% | -80.61% | -34.22% | -20.67% | -19.85% |
| Return on Tangible Assets | -80.71% | -69.88% | -31.28% | -19.53% | -22.19% |
| Earnings Yield | -52.16% | -204.96% | -48.19% | -21.36% | -13.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 3.99 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.51 | 0.06 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.09 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.14 | 0.02 |
| Cash Conversion Cycle | -91.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 91.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.78 | -12.42 | -13.04 | -13.72 | -10.40 |
| Free Cash Flow Per Share | -8.82 | -12.46 | -13.26 | -15.69 | -15.80 |
| Dividend Paid and CapEx Coverage Ratio | -192.34 | -349.99 | -60.94 | -6.98 | -1.93 |
| Capital Expenditure Coverage Ratio | -192.34 | -349.99 | -60.94 | -6.98 | -1.93 |
| Operating Cash Flow Coverage Ratio | -2.94 | -2.75 | -2.59 | -2.50 | -1.86 |
| Operating Cash Flow to Sales Ratio | -4167.33 | -2662.20 | -1259.18 | -2.00 | -11.85 |
| Free Cash Flow Yield | -28.66% | -97.32% | -34.17% | -22.61% | -10.21% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.92 | -9.77 | -2.08 | -4.68 | -7.51 |
| Price-to-Sales (P/S) Ratio | 14614.51 | 2743.40 | 3745.44 | 10.12 | 176.41 |
| Price-to-Book (P/B) Ratio | 2.12 | 0.44 | 0.74 | 1.03 | 2.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.49 | -1.03 | -2.93 | -4.42 | -9.80 |
| Price-to-Operating Cash Flow Ratio | -3.51 | -1.03 | -2.97 | -5.06 | -14.88 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.24 | -0.08 | 0.17 | -0.34 |
| Enterprise Value Multiple | -1.97 | -0.60 | -1.78 | -4.74 | -8.22 |
| Enterprise Value | 516.94M | 120.72M | 404.43M | 801.52M | 1.65B |
| EV to EBITDA | -1.97 | -0.60 | -1.78 | -4.74 | -8.22 |
| EV to Sales | 14359.32 | 1978.99 | 3110.98 | 9.46 | 155.19 |
| EV to Free Cash Flow | -3.43 | -0.74 | -2.43 | -4.14 | -8.62 |
| EV to Operating Cash Flow | -3.45 | -0.74 | -2.47 | -4.73 | -13.09 |
| Tangible Book Value Per Share | 14.52 | 29.28 | 52.19 | 67.45 | 76.61 |
| Shareholders’ Equity Per Share | 14.52 | 29.28 | 52.19 | 67.45 | 76.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 6.85 | 0.88 |
| Net Income Per Share | -16.06 | -26.23 | -18.70 | -14.82 | -20.62 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.56 | 0.95 | 0.98 | 1.17 |
| Research & Development to Revenue | 4407.64 | 2813.16 | 1407.27 | 1.88 | 13.02 |
| SG&A to Revenue | 1253.75 | 853.13 | 515.25 | 1.39 | 8.36 |
| Stock-Based Compensation to Revenue | 1161.92 | 543.34 | 362.18 | 0.00 | 5.84 |
| Income Quality | 0.55 | 0.47 | 0.70 | 0.93 | 0.50 |
Currency in USD

